ABIVAX Société Anonyme

ABIVAX Société Anonyme is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate is obefazimod, which is currently in Phase 3 clinical development for the treatment of moderately to severely active ulcerative colitis (UC), as well as Phase 2b clinical trials for Crohn's disease. The company operates in the healthcare sector within the biotechnology industry, aiming to address significant unmet medical needs in chronic inflammatory conditions.

ABIVAX Société Anonyme is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ABVX. Its shares trade in US Dollars (USD), providing access to investors in the United States and globally. The company is headquartered in Paris, France, but its listing on a US exchange allows it to tap into a broader investor base and benefit from the liquidity and visibility of the Nasdaq market.

ABIVAX Société Anonyme operates in the healthcare sector, specifically within the biotechnology industry. As a clinical-stage biotechnology company, it focuses on researching and developing novel therapeutics for chronic inflammatory diseases. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and the potential for significant returns if drugs successfully reach the market. ABIVAX's work in harnessing the body's natural regulatory mechanisms places it at the forefront of innovative approaches to treating conditions like ulcerative colitis and Crohn's disease.

ABIVAX Société Anonyme is headquartered in Paris, France, and was incorporated in 2013. While the company is based in Europe, its primary listing on the Nasdaq in the United States indicates a global strategic focus. The company's clinical trials for its lead candidate obefazimod are likely conducted internationally, targeting patients with chronic inflammatory diseases such as ulcerative colitis and Crohn's disease. The geographic scope of its operations and market reach extends beyond France, aiming to serve patients and healthcare systems worldwide.

ABIVAX's lead drug candidate is obefazimod, a therapeutic designed to stabilize the immune response in patients with chronic inflammatory diseases. Obefazimod is currently in Phase 3 clinical development for the treatment of moderately to severely active ulcerative colitis (UC), and it is also being evaluated in Phase 2b clinical trials for Crohn's disease. These stages indicate that the drug has shown promising results in earlier trials and is now being tested in larger patient populations to confirm its efficacy and safety. If successful, obefazimod could become a significant treatment option for these debilitating conditions.